Clinical Research Trials Archive – Closed Trials

This is our archive of closed clinical trials, which means that they are no longer accepting new participants or have been concluded. Once a research facility has chosen to close the study, it is sorted into the GPS archive by indication. If you are interested in enrolling in a clinical trial, then please browse our list of active clinical studies.

Zip code

Condition


Search Radius:25 Miles
  • 5
  • 10
  • 15
  • 20
  • 25
  • 30
  • 40
  • 50
  • 100
  • 500
  • All

We've found
8,177
archived clinical trials in
Orthopedic

PoC Study to Assess Activity and Safety of SMT C1100 (Ezutromid) in Boys With DMD
A Phase 2 Clinical Study to Assess the Activity and Safety of Utrophin Modulation With SMT C1100 in Ambulatory Paediatric Male Subjects With Duchenne Muscular Dystrophy
Status: Enrolling
Updated:  12/31/1969
University of Utah Hospital and Clinics
702
mi
from 98109
Salt Lake City, UT
PoC Study to Assess Activity and Safety of SMT C1100 (Ezutromid) in Boys With DMD
A Phase 2 Clinical Study to Assess the Activity and Safety of Utrophin Modulation With SMT C1100 in Ambulatory Paediatric Male Subjects With Duchenne Muscular Dystrophy
Status: Enrolling
Updated: 12/31/1969
University of Utah Hospital and Clinics
702
mi
from 98109
Salt Lake City, UT
Click here to add this to my saved trials
PoC Study to Assess Activity and Safety of SMT C1100 (Ezutromid) in Boys With DMD
A Phase 2 Clinical Study to Assess the Activity and Safety of Utrophin Modulation With SMT C1100 in Ambulatory Paediatric Male Subjects With Duchenne Muscular Dystrophy
Status: Enrolling
Updated:  12/31/1969
Heart of England NHS Foundation Trust - Heartlands Hospital
2079
mi
from 98109
Birmingham,
PoC Study to Assess Activity and Safety of SMT C1100 (Ezutromid) in Boys With DMD
A Phase 2 Clinical Study to Assess the Activity and Safety of Utrophin Modulation With SMT C1100 in Ambulatory Paediatric Male Subjects With Duchenne Muscular Dystrophy
Status: Enrolling
Updated: 12/31/1969
Heart of England NHS Foundation Trust - Heartlands Hospital
2079
mi
from 98109
Birmingham,
Click here to add this to my saved trials
PoC Study to Assess Activity and Safety of SMT C1100 (Ezutromid) in Boys With DMD
A Phase 2 Clinical Study to Assess the Activity and Safety of Utrophin Modulation With SMT C1100 in Ambulatory Paediatric Male Subjects With Duchenne Muscular Dystrophy
Status: Enrolling
Updated:  12/31/1969
UCLA David Geffen School of Medicine
962
mi
from 98109
Los Angeles, CA
PoC Study to Assess Activity and Safety of SMT C1100 (Ezutromid) in Boys With DMD
A Phase 2 Clinical Study to Assess the Activity and Safety of Utrophin Modulation With SMT C1100 in Ambulatory Paediatric Male Subjects With Duchenne Muscular Dystrophy
Status: Enrolling
Updated: 12/31/1969
UCLA David Geffen School of Medicine
962
mi
from 98109
Los Angeles, CA
Click here to add this to my saved trials
PoC Study to Assess Activity and Safety of SMT C1100 (Ezutromid) in Boys With DMD
A Phase 2 Clinical Study to Assess the Activity and Safety of Utrophin Modulation With SMT C1100 in Ambulatory Paediatric Male Subjects With Duchenne Muscular Dystrophy
Status: Enrolling
Updated:  12/31/1969
Children's Hosptial Colorado
1026
mi
from 98109
Aurora, CO
PoC Study to Assess Activity and Safety of SMT C1100 (Ezutromid) in Boys With DMD
A Phase 2 Clinical Study to Assess the Activity and Safety of Utrophin Modulation With SMT C1100 in Ambulatory Paediatric Male Subjects With Duchenne Muscular Dystrophy
Status: Enrolling
Updated: 12/31/1969
Children's Hosptial Colorado
1026
mi
from 98109
Aurora, CO
Click here to add this to my saved trials
Virtual vs. Traditional Physical Therapy Following Total Knee Replacement
Virtual Exercise Rehabilitation In-home Therapy: A Randomized Study (VERITAS)
Status: Enrolling
Updated:  12/31/1969
Duke Orthopaedics
2336
mi
from 98109
Durham, NC
Virtual vs. Traditional Physical Therapy Following Total Knee Replacement
Virtual Exercise Rehabilitation In-home Therapy: A Randomized Study (VERITAS)
Status: Enrolling
Updated: 12/31/1969
Duke Orthopaedics
2336
mi
from 98109
Durham, NC
Click here to add this to my saved trials
Virtual vs. Traditional Physical Therapy Following Total Knee Replacement
Virtual Exercise Rehabilitation In-home Therapy: A Randomized Study (VERITAS)
Status: Enrolling
Updated:  12/31/1969
Raleigh Orthopaedics
2356
mi
from 98109
Raleigh, NC
Virtual vs. Traditional Physical Therapy Following Total Knee Replacement
Virtual Exercise Rehabilitation In-home Therapy: A Randomized Study (VERITAS)
Status: Enrolling
Updated: 12/31/1969
Raleigh Orthopaedics
2356
mi
from 98109
Raleigh, NC
Click here to add this to my saved trials
Virtual vs. Traditional Physical Therapy Following Total Knee Replacement
Virtual Exercise Rehabilitation In-home Therapy: A Randomized Study (VERITAS)
Status: Enrolling
Updated:  12/31/1969
University of North Carolina Orhthopedics
2338
mi
from 98109
Chapel Hill, NC
Virtual vs. Traditional Physical Therapy Following Total Knee Replacement
Virtual Exercise Rehabilitation In-home Therapy: A Randomized Study (VERITAS)
Status: Enrolling
Updated: 12/31/1969
University of North Carolina Orhthopedics
2338
mi
from 98109
Chapel Hill, NC
Click here to add this to my saved trials
Virtual vs. Traditional Physical Therapy Following Total Knee Replacement
Virtual Exercise Rehabilitation In-home Therapy: A Randomized Study (VERITAS)
Status: Enrolling
Updated:  12/31/1969
Greensboro Orthopedics
2294
mi
from 98109
Greensboro, NC
Virtual vs. Traditional Physical Therapy Following Total Knee Replacement
Virtual Exercise Rehabilitation In-home Therapy: A Randomized Study (VERITAS)
Status: Enrolling
Updated: 12/31/1969
Greensboro Orthopedics
2294
mi
from 98109
Greensboro, NC
Click here to add this to my saved trials
Platelet-rich Plasma vs. Whole Blood for Gluteus Medius Tendinopathy
Ultrasound-Guided Platelet Rich Plasma Versus Whole Blood Injection for the Treatment of Gluteus Medius Tendinopathy: A Double-Blind Randomized Controlled Study
Status: Enrolling
Updated:  12/31/1969
Hospital for Special Surgery
2402
mi
from 98109
New York, NY
Platelet-rich Plasma vs. Whole Blood for Gluteus Medius Tendinopathy
Ultrasound-Guided Platelet Rich Plasma Versus Whole Blood Injection for the Treatment of Gluteus Medius Tendinopathy: A Double-Blind Randomized Controlled Study
Status: Enrolling
Updated: 12/31/1969
Hospital for Special Surgery
2402
mi
from 98109
New York, NY
Click here to add this to my saved trials
A Study of Ruxolitinib in Combination With Corticosteroids for the Treatment of Steroid-Refractory Acute Graft-Versus-Host Disease (REACH1)
A Single-Cohort, Phase 2 Study of Ruxolitinib in Combination With Corticosteroids for the Treatment of Steroid-Refractory Acute Graft-Versus-Host Disease (REACH1)
Status: Enrolling
Updated:  12/31/1969
Clinical Research Facility
1220
mi
from 98109
Tucson, AZ
A Study of Ruxolitinib in Combination With Corticosteroids for the Treatment of Steroid-Refractory Acute Graft-Versus-Host Disease (REACH1)
A Single-Cohort, Phase 2 Study of Ruxolitinib in Combination With Corticosteroids for the Treatment of Steroid-Refractory Acute Graft-Versus-Host Disease (REACH1)
Status: Enrolling
Updated: 12/31/1969
Clinical Research Facility
1220
mi
from 98109
Tucson, AZ
Click here to add this to my saved trials
A Study of Ruxolitinib in Combination With Corticosteroids for the Treatment of Steroid-Refractory Acute Graft-Versus-Host Disease (REACH1)
A Single-Cohort, Phase 2 Study of Ruxolitinib in Combination With Corticosteroids for the Treatment of Steroid-Refractory Acute Graft-Versus-Host Disease (REACH1)
Status: Enrolling
Updated:  12/31/1969
Clinical Research Facility
959
mi
from 98109
Duarte, CA
A Study of Ruxolitinib in Combination With Corticosteroids for the Treatment of Steroid-Refractory Acute Graft-Versus-Host Disease (REACH1)
A Single-Cohort, Phase 2 Study of Ruxolitinib in Combination With Corticosteroids for the Treatment of Steroid-Refractory Acute Graft-Versus-Host Disease (REACH1)
Status: Enrolling
Updated: 12/31/1969
Clinical Research Facility
959
mi
from 98109
Duarte, CA
Click here to add this to my saved trials
A Study of Ruxolitinib in Combination With Corticosteroids for the Treatment of Steroid-Refractory Acute Graft-Versus-Host Disease (REACH1)
A Single-Cohort, Phase 2 Study of Ruxolitinib in Combination With Corticosteroids for the Treatment of Steroid-Refractory Acute Graft-Versus-Host Disease (REACH1)
Status: Enrolling
Updated:  12/31/1969
Clinical Research Facility
1049
mi
from 98109
La Jolla, CA
A Study of Ruxolitinib in Combination With Corticosteroids for the Treatment of Steroid-Refractory Acute Graft-Versus-Host Disease (REACH1)
A Single-Cohort, Phase 2 Study of Ruxolitinib in Combination With Corticosteroids for the Treatment of Steroid-Refractory Acute Graft-Versus-Host Disease (REACH1)
Status: Enrolling
Updated: 12/31/1969
Clinical Research Facility
1049
mi
from 98109
La Jolla, CA
Click here to add this to my saved trials
A Study of Ruxolitinib in Combination With Corticosteroids for the Treatment of Steroid-Refractory Acute Graft-Versus-Host Disease (REACH1)
A Single-Cohort, Phase 2 Study of Ruxolitinib in Combination With Corticosteroids for the Treatment of Steroid-Refractory Acute Graft-Versus-Host Disease (REACH1)
Status: Enrolling
Updated:  12/31/1969
Clinical Research Facility
962
mi
from 98109
Los Angeles, CA
A Study of Ruxolitinib in Combination With Corticosteroids for the Treatment of Steroid-Refractory Acute Graft-Versus-Host Disease (REACH1)
A Single-Cohort, Phase 2 Study of Ruxolitinib in Combination With Corticosteroids for the Treatment of Steroid-Refractory Acute Graft-Versus-Host Disease (REACH1)
Status: Enrolling
Updated: 12/31/1969
Clinical Research Facility
962
mi
from 98109
Los Angeles, CA
Click here to add this to my saved trials
A Study of Ruxolitinib in Combination With Corticosteroids for the Treatment of Steroid-Refractory Acute Graft-Versus-Host Disease (REACH1)
A Single-Cohort, Phase 2 Study of Ruxolitinib in Combination With Corticosteroids for the Treatment of Steroid-Refractory Acute Graft-Versus-Host Disease (REACH1)
Status: Enrolling
Updated:  12/31/1969
Clinical Research Facility
705
mi
from 98109
Stanford, CA
A Study of Ruxolitinib in Combination With Corticosteroids for the Treatment of Steroid-Refractory Acute Graft-Versus-Host Disease (REACH1)
A Single-Cohort, Phase 2 Study of Ruxolitinib in Combination With Corticosteroids for the Treatment of Steroid-Refractory Acute Graft-Versus-Host Disease (REACH1)
Status: Enrolling
Updated: 12/31/1969
Clinical Research Facility
705
mi
from 98109
Stanford, CA
Click here to add this to my saved trials
A Study of Ruxolitinib in Combination With Corticosteroids for the Treatment of Steroid-Refractory Acute Graft-Versus-Host Disease (REACH1)
A Single-Cohort, Phase 2 Study of Ruxolitinib in Combination With Corticosteroids for the Treatment of Steroid-Refractory Acute Graft-Versus-Host Disease (REACH1)
Status: Enrolling
Updated:  12/31/1969
Clinical Research Facility
1020
mi
from 98109
Denver, CO
A Study of Ruxolitinib in Combination With Corticosteroids for the Treatment of Steroid-Refractory Acute Graft-Versus-Host Disease (REACH1)
A Single-Cohort, Phase 2 Study of Ruxolitinib in Combination With Corticosteroids for the Treatment of Steroid-Refractory Acute Graft-Versus-Host Disease (REACH1)
Status: Enrolling
Updated: 12/31/1969
Clinical Research Facility
1020
mi
from 98109
Denver, CO
Click here to add this to my saved trials
A Study of Ruxolitinib in Combination With Corticosteroids for the Treatment of Steroid-Refractory Acute Graft-Versus-Host Disease (REACH1)
A Single-Cohort, Phase 2 Study of Ruxolitinib in Combination With Corticosteroids for the Treatment of Steroid-Refractory Acute Graft-Versus-Host Disease (REACH1)
Status: Enrolling
Updated:  12/31/1969
Clinical Research Facility
2730
mi
from 98109
Miami, FL
A Study of Ruxolitinib in Combination With Corticosteroids for the Treatment of Steroid-Refractory Acute Graft-Versus-Host Disease (REACH1)
A Single-Cohort, Phase 2 Study of Ruxolitinib in Combination With Corticosteroids for the Treatment of Steroid-Refractory Acute Graft-Versus-Host Disease (REACH1)
Status: Enrolling
Updated: 12/31/1969
Clinical Research Facility
2730
mi
from 98109
Miami, FL
Click here to add this to my saved trials
A Study of Ruxolitinib in Combination With Corticosteroids for the Treatment of Steroid-Refractory Acute Graft-Versus-Host Disease (REACH1)
A Single-Cohort, Phase 2 Study of Ruxolitinib in Combination With Corticosteroids for the Treatment of Steroid-Refractory Acute Graft-Versus-Host Disease (REACH1)
Status: Enrolling
Updated:  12/31/1969
Clinical Research Facility
2527
mi
from 98109
Tampa, FL
A Study of Ruxolitinib in Combination With Corticosteroids for the Treatment of Steroid-Refractory Acute Graft-Versus-Host Disease (REACH1)
A Single-Cohort, Phase 2 Study of Ruxolitinib in Combination With Corticosteroids for the Treatment of Steroid-Refractory Acute Graft-Versus-Host Disease (REACH1)
Status: Enrolling
Updated: 12/31/1969
Clinical Research Facility
2527
mi
from 98109
Tampa, FL
Click here to add this to my saved trials
A Study of Ruxolitinib in Combination With Corticosteroids for the Treatment of Steroid-Refractory Acute Graft-Versus-Host Disease (REACH1)
A Single-Cohort, Phase 2 Study of Ruxolitinib in Combination With Corticosteroids for the Treatment of Steroid-Refractory Acute Graft-Versus-Host Disease (REACH1)
Status: Enrolling
Updated:  12/31/1969
Clinical Research Facility
2178
mi
from 98109
Atlanta, GA
A Study of Ruxolitinib in Combination With Corticosteroids for the Treatment of Steroid-Refractory Acute Graft-Versus-Host Disease (REACH1)
A Single-Cohort, Phase 2 Study of Ruxolitinib in Combination With Corticosteroids for the Treatment of Steroid-Refractory Acute Graft-Versus-Host Disease (REACH1)
Status: Enrolling
Updated: 12/31/1969
Clinical Research Facility
2178
mi
from 98109
Atlanta, GA
Click here to add this to my saved trials
A Study of Ruxolitinib in Combination With Corticosteroids for the Treatment of Steroid-Refractory Acute Graft-Versus-Host Disease (REACH1)
A Single-Cohort, Phase 2 Study of Ruxolitinib in Combination With Corticosteroids for the Treatment of Steroid-Refractory Acute Graft-Versus-Host Disease (REACH1)
Status: Enrolling
Updated:  12/31/1969
Clinical Research Facility
1733
mi
from 98109
Chicago, IL
A Study of Ruxolitinib in Combination With Corticosteroids for the Treatment of Steroid-Refractory Acute Graft-Versus-Host Disease (REACH1)
A Single-Cohort, Phase 2 Study of Ruxolitinib in Combination With Corticosteroids for the Treatment of Steroid-Refractory Acute Graft-Versus-Host Disease (REACH1)
Status: Enrolling
Updated: 12/31/1969
Clinical Research Facility
1733
mi
from 98109
Chicago, IL
Click here to add this to my saved trials
A Study of Ruxolitinib in Combination With Corticosteroids for the Treatment of Steroid-Refractory Acute Graft-Versus-Host Disease (REACH1)
A Single-Cohort, Phase 2 Study of Ruxolitinib in Combination With Corticosteroids for the Treatment of Steroid-Refractory Acute Graft-Versus-Host Disease (REACH1)
Status: Enrolling
Updated:  12/31/1969
Clinical Research Facility
2005
mi
from 98109
Lexington, KY
A Study of Ruxolitinib in Combination With Corticosteroids for the Treatment of Steroid-Refractory Acute Graft-Versus-Host Disease (REACH1)
A Single-Cohort, Phase 2 Study of Ruxolitinib in Combination With Corticosteroids for the Treatment of Steroid-Refractory Acute Graft-Versus-Host Disease (REACH1)
Status: Enrolling
Updated: 12/31/1969
Clinical Research Facility
2005
mi
from 98109
Lexington, KY
Click here to add this to my saved trials
A Study of Ruxolitinib in Combination With Corticosteroids for the Treatment of Steroid-Refractory Acute Graft-Versus-Host Disease (REACH1)
A Single-Cohort, Phase 2 Study of Ruxolitinib in Combination With Corticosteroids for the Treatment of Steroid-Refractory Acute Graft-Versus-Host Disease (REACH1)
Status: Enrolling
Updated:  12/31/1969
Clinical Research Facility
2485
mi
from 98109
Boston, MA
A Study of Ruxolitinib in Combination With Corticosteroids for the Treatment of Steroid-Refractory Acute Graft-Versus-Host Disease (REACH1)
A Single-Cohort, Phase 2 Study of Ruxolitinib in Combination With Corticosteroids for the Treatment of Steroid-Refractory Acute Graft-Versus-Host Disease (REACH1)
Status: Enrolling
Updated: 12/31/1969
Clinical Research Facility
2485
mi
from 98109
Boston, MA
Click here to add this to my saved trials
A Study of Ruxolitinib in Combination With Corticosteroids for the Treatment of Steroid-Refractory Acute Graft-Versus-Host Disease (REACH1)
A Single-Cohort, Phase 2 Study of Ruxolitinib in Combination With Corticosteroids for the Treatment of Steroid-Refractory Acute Graft-Versus-Host Disease (REACH1)
Status: Enrolling
Updated:  12/31/1969
Clinical Research Facility
1794
mi
from 98109
Grand Rapids, MI
A Study of Ruxolitinib in Combination With Corticosteroids for the Treatment of Steroid-Refractory Acute Graft-Versus-Host Disease (REACH1)
A Single-Cohort, Phase 2 Study of Ruxolitinib in Combination With Corticosteroids for the Treatment of Steroid-Refractory Acute Graft-Versus-Host Disease (REACH1)
Status: Enrolling
Updated: 12/31/1969
Clinical Research Facility
1794
mi
from 98109
Grand Rapids, MI
Click here to add this to my saved trials
A Study of Ruxolitinib in Combination With Corticosteroids for the Treatment of Steroid-Refractory Acute Graft-Versus-Host Disease (REACH1)
A Single-Cohort, Phase 2 Study of Ruxolitinib in Combination With Corticosteroids for the Treatment of Steroid-Refractory Acute Graft-Versus-Host Disease (REACH1)
Status: Enrolling
Updated:  12/31/1969
Clinical Research Facility
1393
mi
from 98109
Minneapolis, MN
A Study of Ruxolitinib in Combination With Corticosteroids for the Treatment of Steroid-Refractory Acute Graft-Versus-Host Disease (REACH1)
A Single-Cohort, Phase 2 Study of Ruxolitinib in Combination With Corticosteroids for the Treatment of Steroid-Refractory Acute Graft-Versus-Host Disease (REACH1)
Status: Enrolling
Updated: 12/31/1969
Clinical Research Facility
1393
mi
from 98109
Minneapolis, MN
Click here to add this to my saved trials
A Study of Ruxolitinib in Combination With Corticosteroids for the Treatment of Steroid-Refractory Acute Graft-Versus-Host Disease (REACH1)
A Single-Cohort, Phase 2 Study of Ruxolitinib in Combination With Corticosteroids for the Treatment of Steroid-Refractory Acute Graft-Versus-Host Disease (REACH1)
Status: Enrolling
Updated:  12/31/1969
Clinical Research Facility
2394
mi
from 98109
Hackensack, NJ
A Study of Ruxolitinib in Combination With Corticosteroids for the Treatment of Steroid-Refractory Acute Graft-Versus-Host Disease (REACH1)
A Single-Cohort, Phase 2 Study of Ruxolitinib in Combination With Corticosteroids for the Treatment of Steroid-Refractory Acute Graft-Versus-Host Disease (REACH1)
Status: Enrolling
Updated: 12/31/1969
Clinical Research Facility
2394
mi
from 98109
Hackensack, NJ
Click here to add this to my saved trials
A Study of Ruxolitinib in Combination With Corticosteroids for the Treatment of Steroid-Refractory Acute Graft-Versus-Host Disease (REACH1)
A Single-Cohort, Phase 2 Study of Ruxolitinib in Combination With Corticosteroids for the Treatment of Steroid-Refractory Acute Graft-Versus-Host Disease (REACH1)
Status: Enrolling
Updated:  12/31/1969
Clinical Research Facility
2400
mi
from 98109
New York, NY
A Study of Ruxolitinib in Combination With Corticosteroids for the Treatment of Steroid-Refractory Acute Graft-Versus-Host Disease (REACH1)
A Single-Cohort, Phase 2 Study of Ruxolitinib in Combination With Corticosteroids for the Treatment of Steroid-Refractory Acute Graft-Versus-Host Disease (REACH1)
Status: Enrolling
Updated: 12/31/1969
Clinical Research Facility
2400
mi
from 98109
New York, NY
Click here to add this to my saved trials
A Study of Ruxolitinib in Combination With Corticosteroids for the Treatment of Steroid-Refractory Acute Graft-Versus-Host Disease (REACH1)
A Single-Cohort, Phase 2 Study of Ruxolitinib in Combination With Corticosteroids for the Treatment of Steroid-Refractory Acute Graft-Versus-Host Disease (REACH1)
Status: Enrolling
Updated:  12/31/1969
Clinical Research Facility
2161
mi
from 98109
Rochester, NY
A Study of Ruxolitinib in Combination With Corticosteroids for the Treatment of Steroid-Refractory Acute Graft-Versus-Host Disease (REACH1)
A Single-Cohort, Phase 2 Study of Ruxolitinib in Combination With Corticosteroids for the Treatment of Steroid-Refractory Acute Graft-Versus-Host Disease (REACH1)
Status: Enrolling
Updated: 12/31/1969
Clinical Research Facility
2161
mi
from 98109
Rochester, NY
Click here to add this to my saved trials
A Study of Ruxolitinib in Combination With Corticosteroids for the Treatment of Steroid-Refractory Acute Graft-Versus-Host Disease (REACH1)
A Single-Cohort, Phase 2 Study of Ruxolitinib in Combination With Corticosteroids for the Treatment of Steroid-Refractory Acute Graft-Versus-Host Disease (REACH1)
Status: Enrolling
Updated:  12/31/1969
Clinical Research Facility
2283
mi
from 98109
Charlotte, NC
A Study of Ruxolitinib in Combination With Corticosteroids for the Treatment of Steroid-Refractory Acute Graft-Versus-Host Disease (REACH1)
A Single-Cohort, Phase 2 Study of Ruxolitinib in Combination With Corticosteroids for the Treatment of Steroid-Refractory Acute Graft-Versus-Host Disease (REACH1)
Status: Enrolling
Updated: 12/31/1969
Clinical Research Facility
2283
mi
from 98109
Charlotte, NC
Click here to add this to my saved trials
A Study of Ruxolitinib in Combination With Corticosteroids for the Treatment of Steroid-Refractory Acute Graft-Versus-Host Disease (REACH1)
A Single-Cohort, Phase 2 Study of Ruxolitinib in Combination With Corticosteroids for the Treatment of Steroid-Refractory Acute Graft-Versus-Host Disease (REACH1)
Status: Enrolling
Updated:  12/31/1969
Clinical Research Facility
2020
mi
from 98109
Cleveland, OH
A Study of Ruxolitinib in Combination With Corticosteroids for the Treatment of Steroid-Refractory Acute Graft-Versus-Host Disease (REACH1)
A Single-Cohort, Phase 2 Study of Ruxolitinib in Combination With Corticosteroids for the Treatment of Steroid-Refractory Acute Graft-Versus-Host Disease (REACH1)
Status: Enrolling
Updated: 12/31/1969
Clinical Research Facility
2020
mi
from 98109
Cleveland, OH
Click here to add this to my saved trials
A Study of Ruxolitinib in Combination With Corticosteroids for the Treatment of Steroid-Refractory Acute Graft-Versus-Host Disease (REACH1)
A Single-Cohort, Phase 2 Study of Ruxolitinib in Combination With Corticosteroids for the Treatment of Steroid-Refractory Acute Graft-Versus-Host Disease (REACH1)
Status: Enrolling
Updated:  12/31/1969
Clinical Research Facility
2373
mi
from 98109
Philadelphia, PA
A Study of Ruxolitinib in Combination With Corticosteroids for the Treatment of Steroid-Refractory Acute Graft-Versus-Host Disease (REACH1)
A Single-Cohort, Phase 2 Study of Ruxolitinib in Combination With Corticosteroids for the Treatment of Steroid-Refractory Acute Graft-Versus-Host Disease (REACH1)
Status: Enrolling
Updated: 12/31/1969
Clinical Research Facility
2373
mi
from 98109
Philadelphia, PA
Click here to add this to my saved trials
A Study of Ruxolitinib in Combination With Corticosteroids for the Treatment of Steroid-Refractory Acute Graft-Versus-Host Disease (REACH1)
A Single-Cohort, Phase 2 Study of Ruxolitinib in Combination With Corticosteroids for the Treatment of Steroid-Refractory Acute Graft-Versus-Host Disease (REACH1)
Status: Enrolling
Updated:  12/31/1969
Clinical Research Facility
2132
mi
from 98109
Pittsburgh, PA
A Study of Ruxolitinib in Combination With Corticosteroids for the Treatment of Steroid-Refractory Acute Graft-Versus-Host Disease (REACH1)
A Single-Cohort, Phase 2 Study of Ruxolitinib in Combination With Corticosteroids for the Treatment of Steroid-Refractory Acute Graft-Versus-Host Disease (REACH1)
Status: Enrolling
Updated: 12/31/1969
Clinical Research Facility
2132
mi
from 98109
Pittsburgh, PA
Click here to add this to my saved trials
A Study of Ruxolitinib in Combination With Corticosteroids for the Treatment of Steroid-Refractory Acute Graft-Versus-Host Disease (REACH1)
A Single-Cohort, Phase 2 Study of Ruxolitinib in Combination With Corticosteroids for the Treatment of Steroid-Refractory Acute Graft-Versus-Host Disease (REACH1)
Status: Enrolling
Updated:  12/31/1969
Clinical Research Facility
1970
mi
from 98109
Nashville, TN
A Study of Ruxolitinib in Combination With Corticosteroids for the Treatment of Steroid-Refractory Acute Graft-Versus-Host Disease (REACH1)
A Single-Cohort, Phase 2 Study of Ruxolitinib in Combination With Corticosteroids for the Treatment of Steroid-Refractory Acute Graft-Versus-Host Disease (REACH1)
Status: Enrolling
Updated: 12/31/1969
Clinical Research Facility
1970
mi
from 98109
Nashville, TN
Click here to add this to my saved trials
A Study of Ruxolitinib in Combination With Corticosteroids for the Treatment of Steroid-Refractory Acute Graft-Versus-Host Disease (REACH1)
A Single-Cohort, Phase 2 Study of Ruxolitinib in Combination With Corticosteroids for the Treatment of Steroid-Refractory Acute Graft-Versus-Host Disease (REACH1)
Status: Enrolling
Updated:  12/31/1969
Clinical Research Facility
1682
mi
from 98109
Dallas, TX
A Study of Ruxolitinib in Combination With Corticosteroids for the Treatment of Steroid-Refractory Acute Graft-Versus-Host Disease (REACH1)
A Single-Cohort, Phase 2 Study of Ruxolitinib in Combination With Corticosteroids for the Treatment of Steroid-Refractory Acute Graft-Versus-Host Disease (REACH1)
Status: Enrolling
Updated: 12/31/1969
Clinical Research Facility
1682
mi
from 98109
Dallas, TX
Click here to add this to my saved trials
A Study of Ruxolitinib in Combination With Corticosteroids for the Treatment of Steroid-Refractory Acute Graft-Versus-Host Disease (REACH1)
A Single-Cohort, Phase 2 Study of Ruxolitinib in Combination With Corticosteroids for the Treatment of Steroid-Refractory Acute Graft-Versus-Host Disease (REACH1)
Status: Enrolling
Updated:  12/31/1969
Clinical Research Facility
1790
mi
from 98109
San Antonio, TX
A Study of Ruxolitinib in Combination With Corticosteroids for the Treatment of Steroid-Refractory Acute Graft-Versus-Host Disease (REACH1)
A Single-Cohort, Phase 2 Study of Ruxolitinib in Combination With Corticosteroids for the Treatment of Steroid-Refractory Acute Graft-Versus-Host Disease (REACH1)
Status: Enrolling
Updated: 12/31/1969
Clinical Research Facility
1790
mi
from 98109
San Antonio, TX
Click here to add this to my saved trials
A Study of Ruxolitinib in Combination With Corticosteroids for the Treatment of Steroid-Refractory Acute Graft-Versus-Host Disease (REACH1)
A Single-Cohort, Phase 2 Study of Ruxolitinib in Combination With Corticosteroids for the Treatment of Steroid-Refractory Acute Graft-Versus-Host Disease (REACH1)
Status: Enrolling
Updated:  12/31/1969
Clinical Research Facility
701
mi
from 98109
Salt Lake City, UT
A Study of Ruxolitinib in Combination With Corticosteroids for the Treatment of Steroid-Refractory Acute Graft-Versus-Host Disease (REACH1)
A Single-Cohort, Phase 2 Study of Ruxolitinib in Combination With Corticosteroids for the Treatment of Steroid-Refractory Acute Graft-Versus-Host Disease (REACH1)
Status: Enrolling
Updated: 12/31/1969
Clinical Research Facility
701
mi
from 98109
Salt Lake City, UT
Click here to add this to my saved trials
A Study of Ruxolitinib in Combination With Corticosteroids for the Treatment of Steroid-Refractory Acute Graft-Versus-Host Disease (REACH1)
A Single-Cohort, Phase 2 Study of Ruxolitinib in Combination With Corticosteroids for the Treatment of Steroid-Refractory Acute Graft-Versus-Host Disease (REACH1)
Status: Enrolling
Updated:  12/31/1969
Clinical Research Facility
2
mi
from 98109
Seattle, WA
A Study of Ruxolitinib in Combination With Corticosteroids for the Treatment of Steroid-Refractory Acute Graft-Versus-Host Disease (REACH1)
A Single-Cohort, Phase 2 Study of Ruxolitinib in Combination With Corticosteroids for the Treatment of Steroid-Refractory Acute Graft-Versus-Host Disease (REACH1)
Status: Enrolling
Updated: 12/31/1969
Clinical Research Facility
2
mi
from 98109
Seattle, WA
Click here to add this to my saved trials
A Study of Ruxolitinib in Combination With Corticosteroids for the Treatment of Steroid-Refractory Acute Graft-Versus-Host Disease (REACH1)
A Single-Cohort, Phase 2 Study of Ruxolitinib in Combination With Corticosteroids for the Treatment of Steroid-Refractory Acute Graft-Versus-Host Disease (REACH1)
Status: Enrolling
Updated:  12/31/1969
Clinical Research Facility
1616
mi
from 98109
Madison, WI
A Study of Ruxolitinib in Combination With Corticosteroids for the Treatment of Steroid-Refractory Acute Graft-Versus-Host Disease (REACH1)
A Single-Cohort, Phase 2 Study of Ruxolitinib in Combination With Corticosteroids for the Treatment of Steroid-Refractory Acute Graft-Versus-Host Disease (REACH1)
Status: Enrolling
Updated: 12/31/1969
Clinical Research Facility
1616
mi
from 98109
Madison, WI
Click here to add this to my saved trials
A Study of Ruxolitinib in Combination With Corticosteroids for the Treatment of Steroid-Refractory Acute Graft-Versus-Host Disease (REACH1)
A Single-Cohort, Phase 2 Study of Ruxolitinib in Combination With Corticosteroids for the Treatment of Steroid-Refractory Acute Graft-Versus-Host Disease (REACH1)
Status: Enrolling
Updated:  12/31/1969
Clinical Research Facility
1681
mi
from 98109
Milwaukee, WI
A Study of Ruxolitinib in Combination With Corticosteroids for the Treatment of Steroid-Refractory Acute Graft-Versus-Host Disease (REACH1)
A Single-Cohort, Phase 2 Study of Ruxolitinib in Combination With Corticosteroids for the Treatment of Steroid-Refractory Acute Graft-Versus-Host Disease (REACH1)
Status: Enrolling
Updated: 12/31/1969
Clinical Research Facility
1681
mi
from 98109
Milwaukee, WI
Click here to add this to my saved trials
A Study of Ruxolitinib in Combination With Corticosteroids for the Treatment of Steroid-Refractory Acute Graft-Versus-Host Disease (REACH1)
A Single-Cohort, Phase 2 Study of Ruxolitinib in Combination With Corticosteroids for the Treatment of Steroid-Refractory Acute Graft-Versus-Host Disease (REACH1)
Status: Enrolling
Updated:  12/31/1969
Clinical Research Facility
2450
mi
from 98109
Gainesville, FL
A Study of Ruxolitinib in Combination With Corticosteroids for the Treatment of Steroid-Refractory Acute Graft-Versus-Host Disease (REACH1)
A Single-Cohort, Phase 2 Study of Ruxolitinib in Combination With Corticosteroids for the Treatment of Steroid-Refractory Acute Graft-Versus-Host Disease (REACH1)
Status: Enrolling
Updated: 12/31/1969
Clinical Research Facility
2450
mi
from 98109
Gainesville, FL
Click here to add this to my saved trials
A Study of Ruxolitinib in Combination With Corticosteroids for the Treatment of Steroid-Refractory Acute Graft-Versus-Host Disease (REACH1)
A Single-Cohort, Phase 2 Study of Ruxolitinib in Combination With Corticosteroids for the Treatment of Steroid-Refractory Acute Graft-Versus-Host Disease (REACH1)
Status: Enrolling
Updated:  12/31/1969
Clinical Research Facility
1720
mi
from 98109
Saint Louis, MO
A Study of Ruxolitinib in Combination With Corticosteroids for the Treatment of Steroid-Refractory Acute Graft-Versus-Host Disease (REACH1)
A Single-Cohort, Phase 2 Study of Ruxolitinib in Combination With Corticosteroids for the Treatment of Steroid-Refractory Acute Graft-Versus-Host Disease (REACH1)
Status: Enrolling
Updated: 12/31/1969
Clinical Research Facility
1720
mi
from 98109
Saint Louis, MO
Click here to add this to my saved trials
A Study of Ruxolitinib in Combination With Corticosteroids for the Treatment of Steroid-Refractory Acute Graft-Versus-Host Disease (REACH1)
A Single-Cohort, Phase 2 Study of Ruxolitinib in Combination With Corticosteroids for the Treatment of Steroid-Refractory Acute Graft-Versus-Host Disease (REACH1)
Status: Enrolling
Updated:  12/31/1969
Clinical Research Facility
1967
mi
from 98109
Cincinnati, OH
A Study of Ruxolitinib in Combination With Corticosteroids for the Treatment of Steroid-Refractory Acute Graft-Versus-Host Disease (REACH1)
A Single-Cohort, Phase 2 Study of Ruxolitinib in Combination With Corticosteroids for the Treatment of Steroid-Refractory Acute Graft-Versus-Host Disease (REACH1)
Status: Enrolling
Updated: 12/31/1969
Clinical Research Facility
1967
mi
from 98109
Cincinnati, OH
Click here to add this to my saved trials
A Study of Ruxolitinib in Combination With Corticosteroids for the Treatment of Steroid-Refractory Acute Graft-Versus-Host Disease (REACH1)
A Single-Cohort, Phase 2 Study of Ruxolitinib in Combination With Corticosteroids for the Treatment of Steroid-Refractory Acute Graft-Versus-Host Disease (REACH1)
Status: Enrolling
Updated:  12/31/1969
Clinical Research Facility
2161
mi
from 98109
Morgantown, WV
A Study of Ruxolitinib in Combination With Corticosteroids for the Treatment of Steroid-Refractory Acute Graft-Versus-Host Disease (REACH1)
A Single-Cohort, Phase 2 Study of Ruxolitinib in Combination With Corticosteroids for the Treatment of Steroid-Refractory Acute Graft-Versus-Host Disease (REACH1)
Status: Enrolling
Updated: 12/31/1969
Clinical Research Facility
2161
mi
from 98109
Morgantown, WV
Click here to add this to my saved trials
Vagal Nerve Stimulation to Reduce Inflammation and Hyperadrenergia
A Study of Safety and Autonomic Responses to Non-Invasive Vagal Stimulation in Persons With Spinal Cord Injury and Non-Disabled Controls Both With and Without Inflammatory Stress
Status: Enrolling
Updated:  12/31/1969
The Miami Project to Cure Paralysis/ University of Miami
2731
mi
from 98109
Miami, FL
Vagal Nerve Stimulation to Reduce Inflammation and Hyperadrenergia
A Study of Safety and Autonomic Responses to Non-Invasive Vagal Stimulation in Persons With Spinal Cord Injury and Non-Disabled Controls Both With and Without Inflammatory Stress
Status: Enrolling
Updated: 12/31/1969
The Miami Project to Cure Paralysis/ University of Miami
2731
mi
from 98109
Miami, FL
Click here to add this to my saved trials
Effects of Botulinum Toxin on Muscle and Brain Activity
Physiological Effects of Botulinum Toxin Therapy in Primary Cervical Dystonia
Status: Enrolling
Updated:  12/31/1969
University of Florida
2452
mi
from 98109
Gainesville, FL
Effects of Botulinum Toxin on Muscle and Brain Activity
Physiological Effects of Botulinum Toxin Therapy in Primary Cervical Dystonia
Status: Enrolling
Updated: 12/31/1969
University of Florida
2452
mi
from 98109
Gainesville, FL
Click here to add this to my saved trials
A Prospective Study Of Biomarkers Of Skeletal Muscle Atrophy
A Single-Center, Prospective Study to Evaluate Biomarkers of Skeletal Muscle Atrophy in Sarcopenia
Status: Enrolling
Updated:  12/31/1969
University of Florida Institute on Aging
2453
mi
from 98109
Gainesville, FL
A Prospective Study Of Biomarkers Of Skeletal Muscle Atrophy
A Single-Center, Prospective Study to Evaluate Biomarkers of Skeletal Muscle Atrophy in Sarcopenia
Status: Enrolling
Updated: 12/31/1969
University of Florida Institute on Aging
2453
mi
from 98109
Gainesville, FL
Click here to add this to my saved trials
Safety of Intravenous Neridronic Acid in CRPS
Open-label Safety Trial of Intravenous Neridronic Acid in Subjects With Complex Regional Pain Syndrome (CRPS)
Status: Enrolling
Updated:  12/31/1969
US016: North Star Medical Research, LLC
2019
mi
from 98109
Middleburg Heights, OH
Safety of Intravenous Neridronic Acid in CRPS
Open-label Safety Trial of Intravenous Neridronic Acid in Subjects With Complex Regional Pain Syndrome (CRPS)
Status: Enrolling
Updated: 12/31/1969
US016: North Star Medical Research, LLC
2019
mi
from 98109
Middleburg Heights, OH
Click here to add this to my saved trials
Safety of Intravenous Neridronic Acid in CRPS
Open-label Safety Trial of Intravenous Neridronic Acid in Subjects With Complex Regional Pain Syndrome (CRPS)
Status: Enrolling
Updated:  12/31/1969
US023: Axios Research, LLC
701
mi
from 98109
Salt Lake City, UT
Safety of Intravenous Neridronic Acid in CRPS
Open-label Safety Trial of Intravenous Neridronic Acid in Subjects With Complex Regional Pain Syndrome (CRPS)
Status: Enrolling
Updated: 12/31/1969
US023: Axios Research, LLC
701
mi
from 98109
Salt Lake City, UT
Click here to add this to my saved trials
Safety of Intravenous Neridronic Acid in CRPS
Open-label Safety Trial of Intravenous Neridronic Acid in Subjects With Complex Regional Pain Syndrome (CRPS)
Status: Enrolling
Updated:  12/31/1969
US028: Quality of Life Medical and Research Centers LLC
1221
mi
from 98109
Tucson, AZ
Safety of Intravenous Neridronic Acid in CRPS
Open-label Safety Trial of Intravenous Neridronic Acid in Subjects With Complex Regional Pain Syndrome (CRPS)
Status: Enrolling
Updated: 12/31/1969
US028: Quality of Life Medical and Research Centers LLC
1221
mi
from 98109
Tucson, AZ
Click here to add this to my saved trials
Safety of Intravenous Neridronic Acid in CRPS
Open-label Safety Trial of Intravenous Neridronic Acid in Subjects With Complex Regional Pain Syndrome (CRPS)
Status: Enrolling
Updated:  12/31/1969
US044: Woodland Research Northwest
1633
mi
from 98109
Rogers, AR
Safety of Intravenous Neridronic Acid in CRPS
Open-label Safety Trial of Intravenous Neridronic Acid in Subjects With Complex Regional Pain Syndrome (CRPS)
Status: Enrolling
Updated: 12/31/1969
US044: Woodland Research Northwest
1633
mi
from 98109
Rogers, AR
Click here to add this to my saved trials
Safety of Intravenous Neridronic Acid in CRPS
Open-label Safety Trial of Intravenous Neridronic Acid in Subjects With Complex Regional Pain Syndrome (CRPS)
Status: Enrolling
Updated:  12/31/1969
US022: Core Healthcare Group
977
mi
from 98109
Cerritos, CA
Safety of Intravenous Neridronic Acid in CRPS
Open-label Safety Trial of Intravenous Neridronic Acid in Subjects With Complex Regional Pain Syndrome (CRPS)
Status: Enrolling
Updated: 12/31/1969
US022: Core Healthcare Group
977
mi
from 98109
Cerritos, CA
Click here to add this to my saved trials
Safety of Intravenous Neridronic Acid in CRPS
Open-label Safety Trial of Intravenous Neridronic Acid in Subjects With Complex Regional Pain Syndrome (CRPS)
Status: Enrolling
Updated:  12/31/1969
US003: Samaritan Center for Medical Research
719
mi
from 98109
Los Gatos, CA
Safety of Intravenous Neridronic Acid in CRPS
Open-label Safety Trial of Intravenous Neridronic Acid in Subjects With Complex Regional Pain Syndrome (CRPS)
Status: Enrolling
Updated: 12/31/1969
US003: Samaritan Center for Medical Research
719
mi
from 98109
Los Gatos, CA
Click here to add this to my saved trials